Open an Account
search icon
3
NOTIFICATIONS
Best Algo trading app in India
Bigul

Cadila Healthcare Ltd reply to clarification sought by the exchange

 The Exchange had sought clarification from Cadila Healthcare Ltd with respect to news appearing in DNA on December 17, 2014 titled "Cadila's US Arm recalls 63,648 bottles of benzonatate capsules."Cadila Healthcare Ltd replied stating "the recall by our US subsidiary was voluntary and a class-III type recall, which means that the use of the product is not likely to cause any adverse health consequences. There is no material impact."
17-12-2014
Bigul

Clarification sought from Cadila Healthcare Ltd

 The Exchange has sought clarification from Cadila Healthcare Ltd with respect to news article appearing in DNA on December 17, 2014 titled "Cadila's US Arm recalls 63,648 bottles of benzonatate capsules." The reply is awaited.
17-12-2014
Bigul

Zydus launches world's first biosimilar of Adalimumab

 Cadila Healthcare Ltd has informed BSE regarding a Press Release dated December 09, 2014, titled "Zydus launches world's first biosimilar of Adalimumab".
09-12-2014
Bigul

Resignation of Director

 Cadila Healthcare Ltd has informed BSE that the Directors of the Company vide circular resolution approved the resignation of Shri. Apurva S. Diwanji.The resignation has been received and taken on record on December 04, 2014.
04-12-2014
Bigul

Disclosures under Reg.13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992

 Cadila Healthcare Ltd has submitted the disclosures under Reg.13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992
02-12-2014
Bigul

Disclosures under Reg.13(4) of SEBI (Prohibition of Insider Trading) Regulations, 1992

 Ganesh N Nayak has submitted the disclosures under Reg.13(4) of SEBI (Prohibition of Insider Trading) Regulations, 1992
02-12-2014
Bigul

Results Press Release

 Cadila Healthcare Ltd has submitted to BSE a copy of the Results Press Release for the period ended September 30, 2014.
11-11-2014
Bigul

Announces Q2 results & Limited Review Report for the Quarter ended September 30, 2014

 Cadila Healthcare Ltd has announced the following results for the quarter ended September 30, 2014:The Unaudited Standalone results for the Quarter ended September 30, 2014The Company has posted a net profit of Rs. 3656.10 million for the quarter ended September 30, 2014 as compared to Rs. 1517.60 million for the quarter ended September 30, 2013. Total Income has increased from Rs. 9936.90 million for the quarter ended September 30,...
06-11-2014
Bigul

Shareholding Pattern For September 30, 2014

 Cadila Healthcare Ltd has informed BSE about the Shareholding Pattern as on September 30, 2014.
16-10-2014
Bigul

Q2 results on Nov 06, 2014

 Cadila Healthcare Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on November 06, 2014, inter alia, to consider and approve the unaudited financial results for the quarter/half-year ended on September 30, 2014 (Q2).Further, as per code of conduct for prevention of Insider Trading adopted by the Company under SEBI (Prohibition of Insider Trading) Regulations, 1992, the Trading Window will remain close...
13-10-2014
Next Page
Close

Let's Open Free Demat Account